Kromek’s Capital Markets Day 2025
Capital Markets Day 2025
As a global leader in advanced imaging and CBRN (Chemical, Biological, Radiological, and Nuclear) detection technology, Kromek is committed to delivering best-in-class solutions that drive safer, healthier communities worldwide. With a proven track record of innovation and robust year-on-year growth, Kromek is targeting medium-term revenues exceeding £60 million and a 30% EBITDA margin, building on the momentum from our expanding partnerships and strong divisional performance in Advanced Imaging and CBRN Detection.
Explore videos and a presentation from Arnab Basu our CEO, Claire Burgess, our CFO, as well as the senior management team, discussing our business foundations, leadership vision, and the strategic value we deliver across the Group. Learn more about our two businesses Advanced Imaging and CBRN Detection and hear why they are two growth pillars for us.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Kromek. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Kromek a question about this update.